Prognostic value of postoperative complication for early recurrence after curative resection of hepatocellular carcinoma

被引:0
作者
Masataka Amisaki [1 ]
Hiroaki Saito [1 ]
Naruo Tokuyasu [1 ]
Teruhisa Sakamoto [1 ]
Soichiro Honjo [1 ]
Yoshiyuki Fujiwara [1 ]
机构
[1] Division of Surgical Oncology,Department of Surgery,School of Medicine,Tottori University Faculty of Medicine
关键词
Neoplasm metastasis; Complications; Risk factors; Hepatocellular carcinoma;
D O I
暂无
中图分类号
R735.7 [肝肿瘤];
学科分类号
100214 ;
摘要
Background: Postoperative complications may adversely affect oncological outcomes. The aim of this study was to evaluate the impact of postoperative complications on early-phase recurrence after curative resection for hepatocellular carcinoma(HCC).Methods: We included 145 HCC patients who underwent initial and curative resection between January2004 and December 2013. Postoperative complications of grade III or higher based on Clavien–Dindo classification were defined as clinically relevant postoperative complications. Recurrence within two years after hepatectomy was defined as early-phase recurrence.Results: Thirty-eight patients(26%) developed postoperative complications. The only predictive factor for postoperative complication was longer operative duration(P = 0.037). The disease-specific survival rate of patients with complication was lower than that of patients without complications(P = 0.015). Earlyphase recurrence was observed in 20/38(53%) patients who suffered postoperative complications and36/107(34%) patients with no complications, which was statistically significant(P = 0.039). Multivariate analysis identified four factors contributing to early-phase recurrence: high serum AFP level(P = 0.042),multiple tumors(P < 0.001), poor differentiation(P = 0.036) and presence of postoperative complication(P = 0.039).Conclusions: Postoperative complication is an independent prognostic factor for early-phase recurrence after curative resection of HCC. Close observation of patients with postoperative complications may be a necessary treatment strategy for HCC.
引用
收藏
页码:323 / 329
页数:7
相关论文
共 22 条
  • [1] Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients[J]. Feng Xia,Li-Li Wu,Wan-Yee Lau,Hong-Bo Huan,Xu-Dong Wen,Kuan-Sheng Ma,Xiao-Wu Li,Ping Bie.World Journal of Gastroenterology. 2016(23)
  • [2] Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma[J]. Jiang Li,Yu Hou,Xiao-Bei Cai,Bin Liu.World Journal of Gastroenterology. 2016(15)
  • [3] Preoperative serum liver enzyme markers for predicting early recurrence after curative resection of hepatocellular carcinoma[J]. Zhong-Xia Wang,Chun-Ping Jiang,Yin Cao,Guang Zhang,Wei-Bo Chen,Yi-Tao Ding.Hepatobiliary & Pancreatic Diseases International. 2015(02)
  • [4] Risk factors for early recurrence of small hepatocellular carcinoma after curative resection[J]. Yan-Ming Zhou,Jia-Mei Yang,Bin Li,Zheng-Feng Yin,Feng Xu,Bin Wang,Wen Xu and Tong Kan Department of Hepato-Biliary-Pancreato-Vascular Surgery,First Xiamen Hospital,Fujian Medical University,Xiamen 361003,China;Department of Special Treatment,Department of Molecular Oncology,Department of Pathology,Eastern Hepatobiliary Surgery Hospital,Second Military Medical University,Shanghai 200438,China.Hepatobi
  • [5] Postoperative complications are predictive of poor prognosis in hepatocellular carcinoma
    Harimoto, Norifumi
    Shirabe, Ken
    Ikegami, Toru
    Yoshizumi, Tomoharu
    Maeda, Takashi
    Kajiyama, Kiyoshi
    Yamanaka, Takeharu
    Maehara, Yoshihiko
    [J]. JOURNAL OF SURGICAL RESEARCH, 2015, 199 (02) : 470 - 477
  • [6] Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial[J] . Jordi Bruix,Tadatoshi Takayama,Vincenzo Mazzaferro,Gar-Yang Chau,Jiamei Yang,Masatoshi Kudo,Jianqiang Cai,Ronnie T Poon,Kwang-Hyub Han,Won Young Tak,Han Chu Lee,Tianqiang Song,Sasan Roayaie,Luigi Bolondi,Kwan Sik Lee,Masatoshi Makuuchi,Fabricio Souza,Marie-Aude Le Berre,Gerold Meinhardt,Josep M Llovet.The Lancet Oncology . 2015 (13)
  • [7] Treatment Options and Surveillance Strategies After Therapy for Hepatocellular Carcinoma
    Hatzaras, Ioannis
    Bischof, Danielle A.
    Fahy, Bridget
    Cosgrove, David
    Pawlik, Timothy M.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (03) : 758 - 766
  • [8] Impact of complications on long-term survival after resection of colorectal liver metastases
    Mavros, M. N.
    de Jong, M.
    Dogeas, E.
    Hyder, O.
    Pawlik, T. M.
    [J]. BRITISH JOURNAL OF SURGERY, 2013, 100 (05) : 711 - 718
  • [9] Liver resection for hepatocellular carcinoma in patients without cirrhosis[J] . A. Thelen,C. Benckert,H.‐M. Tautenhahn,H.‐M. Hau,M. Bartels,J. Linnemann,J. Bertolini,M. Moche,C. Wittekind,S. Jonas.Br J Surg . 2012 (1)
  • [10] New insights into chronic inflammation-induced immunosuppression
    Kanterman, Julia
    Sade-Feldman, Moshe
    Baniyash, Michal
    [J]. SEMINARS IN CANCER BIOLOGY, 2012, 22 (04) : 307 - 318